Background. Intravenous lidocaine infusion has been shown to affect postoperative pain intensity. This present study was performed to assess the effect of intra-and postoperative lidocaine infusion on postoperative functional walking capacity, as a measure of surgical recovery.
Intravenous lidocaine infusion has been used as an adjuvant during and after surgery in patients undergoing retropubic prostatectomy, laparoscopic cholecystectomy, and laparoscopic colon resection; it is associated with a significant postoperative opioid-sparing effect, earlier return of bowel function or shorter hospital stay. 1 -3 Animal and human studies have shown analgesic, antihyperalgesic, and anti-inflammatory properties of i.v. lidocaine, 4 5 which could explain its effect in attenuating visceral pain associated with dissection of pelvic structures.
Surgical outcome has traditionally been reported in terms of mortality and complication rate. However, with major advances in surgical technology and anaesthesia, mortality and morbidity have become rare events. Similarly, the length of hospital stay has been used as a measure of outcome, but is influenced by the health-care system and the administrative culture. Recently, there has been some interest in assessing the influence of therapeutic interventions on the process of surgical recovery or return to baseline, with a particular emphasis on patient-reported outcomes of well-being.
Physical activity is an important aspect of day-to-day life, and tests of functional exercise capacity like walking tests reflect every day activity. 8 These can be influenced by health status, pain, fatigue, and can help to quantify the recovery process. Although different walking tests (12, 6 , and 2 min walking tests: 12MWT, 6MWT, 2MWT) indicate aspects of functional exercise capacity, the 2MWT has been found more suitable for patients in compromised health states in the early postoperative period. 9 10 Walking test is a measure that could be administered as part of an assessment to determine functional performance, to evaluate treatment effectiveness, or to assess readiness for discharge.
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This prospective, randomized, controlled trial was designed to analyse the effect of intraoperative and postoperative lidocaine infusion on the immediate postoperative functional walking capacity and other measures of recovery such as consumption of opioids and return of bowel function. It was hypothesized that by attenuating the inflammatory response and reducing analgesic requirements, lidocaine infusion would improve the capacity to mobilize, thus promoting earlier recovery. ), chronic use of opioids, allergy to local anaesthetics, or inability to comprehend pain assessments. Patients were instructed before surgery in the use of the visual analogue scale (VAS) to assess pain and fatigue. Before induction of anaesthesia, patients were randomly assigned (using a computergenerated randomization schedule and sealed brown envelopes) to two groups of 20 patients each: lidocaine group receiving an intraoperative and postoperative i.v. infusion of lidocaine, and control group receiving an equivalent i.v. infusion of saline 0.9%.
Methods

Patients
Anaesthesia and intraoperative care
Upon arrival in the operating theatre, baseline values of heart rate (HR), arterial pressure, oxygen saturation, and bispectral index (BIS) were recorded. The anaesthesiologists (S.L. and F.C.) who executed the study protocol were blinded to the group allocation and were not involved in preoperative or postoperative data collection. After premedication with i. ) were recorded, and treated with i.v. boluses of phenylnephrine 40 mg or atropine 0.4 mg, respectively. All patients received ketorolac 15 mg i.v. Desflurane was discontinued after the last skin suture, and intermittent doses up to 0.08 mg kg 21 of morphine were given i.v. at return of spontaneous respiration. Lidocaine and the saline infusions were discontinued before patients left the operating theatre.
All operations were performed using a standard laparoscopic technique with infiltration of bupivacaine 0.25% with adrenaline 1:200 000 at the trocar entry ports.
Postoperative analgesia and surgical care
Lidocaine infusion 1 ml kg 21 h 21 (or equivalent volume of saline 0.9%) was recommenced in the PACU and continued for 24 h. PCA morphine (1 mg bolus, 7 min lockout) was started in PACU and continued for 48 h. Patients also received acetaminophen 1.0 g 6 hourly and naproxen 500 mg 12 hourly for the first 72 h. Once PCA morphine was discontinued, patients were offered oxycodone 5 -10 mg 4 hourly if the VAS (0¼no pain and 10¼ excruciating pain) was .3 at rest. Ondansetron 2 mg i.v. was prescribed for persistent nausea (lasting .5 min) or vomiting. An i.v. infusion of dextrose 5% and saline 0.45% was started after surgery and continued for up to 48 h until the patients were tolerating oral fluids. Clear fluids were allowed during the first 24 h, and if tolerated, liquid diet and full diet were then offered. Starting on the first postoperative day, patients in both groups were encouraged by the nurses to mobilize twice a day, whether sitting or walking.
Readiness for hospital discharge was determined according to the following criteria: tolerance of solid food, passage of stool, absence of infection, VAS pain score ,3, and ambulation without assistance. Patients were seen 4 weeks after surgery, at which time any complications were recorded. For patients re-admitted within 30 days of discharge, the reason for the readmission was recorded.
Outcome measures
The 2MWT This was measured before surgery and in the early afternoon (between 1:00 and 5:00 pm) of the first, second, and third postoperative day. Patients were asked to walk back and forth along a 15 m stretch of hallway as much as they could over a period of 2 min. Standardized encouragement ('you are doing well' or 'good, keep going') was given every 30 s. To ensure safety, the evaluator walked behind the patient. Patients were told that they could rest if necessary, and they were allowed to use their regular walking aids. Any i.v. lines, tubes, or PCA pumps were attached to an i.v. pole and pushed by the patient. The distance covered was then recorded in metres. If the patient was unwilling or unable to walk, 0 was recorded for that day. Baseline predicted 2MWT distance was calculated using gender-specific reference equations for the 6MWT, which were then divided by 3 to estimate the 2MWT distance.
Secondary outcomes were morphine consumption during the first two postoperative days and recovery of gastrointestinal function. Pain intensity was assessed using the VAS every afternoon after 1:00 pm for the first 3 postoperative days, sitting on the bed at rest, on coughing and walking. PCA morphine consumption was recorded every 24 h for the first 2 postoperative days. The number of hours until first passage of gas and first bowel movement, and hours to first full diet from surgery were recorded daily at bedside.
Statistical analysis
All data are presented in the tables as means (SD), median [interquartile range], absolute values ( percentage), or relative number of patients. Comparisons for each characteristic and clinical variable among the two groups were performed by Student's t-test, Wilcoxon rank-sum test, or Pearson x 2 test depending on the type of the variable under study and the sample distribution. Non-parametric correlations were performed with Spearman test. Univariate linear regressions were used for normally distributed, continuous variables to estimate the extent to which key explanatory variables predicted change in functional walking capacity over the perioperative period. The level of significance was set at P,0.05. All analyses were performed with the Intercooled Stata 9.2 statistical package (Stata Corporation, College Station, TX, USA).
The primary outcome was functional walking capacity as measured by the 2MWT. Calculations for sample size were based on a previous study 12 in which a change in 20 m in 6MWT was considered to be clinically meaningful. Twenty subjects in each group were sufficient to detect a 15% less decrease in 2MWT in the lidocaine group compared with the control group, with a type-1 error of 0.05 and a power of 80%.
Results
Patient characteristics
The study groups had similar characteristics (Table 1) . Co-morbidities included hypertension, non-insulin-dependent diabetes, hypercholesterolemia, coronary artery disease, and asthma. There were three patients with intraoperative bleeding (two in the lidocaine group and one in the control group) and only one needed blood transfusion. There were no conversions to open surgery. There was no significant difference in the consumption of PCA on the first postoperative day. On the second day, 70% of the patients in the lidocaine group and 30% in the control group did not use PCA morphine (P¼0.011). Total morphine consumption over the 2 postoperative days was less in the lidocaine group though this difference was not statistically significant. Postoperative complications included bleeding, infection, and bladder leak. There was one re-admission in the lidocaine group for bleeding, which was resolved within 15 h. Return of bowel function, readiness for discharge, and length of hospital stay were similar in both groups. BIS values were 48 (SD 8) in the lidocaine group and 46 (9) in the control group, respectively, and end-tidal concentrations of desflurane 5.6 (1.1)% in the lidocaine group and 6.3 (1.6)% in the control group, respectively.
Preoperative values of 2MWT were similar in both groups and accounted for approximately 60% of the predicted values based on Canadian norms (Table 2) . On the first day after surgery, the average 2MWT in both groups decreased significantly when compared with the preoperative value (P,0.01) (Fig. 1) . However, the decrease in the control group was significantly greater, with an average difference of 26 m between the two groups. There was no difference between the two groups on the second and third postoperative days.
Median VAS scores were ,3 in both groups at rest, ,4 on coughing, and ,2 on walking in both groups on all postoperative days; median VAS fatigue scores were ,3 in both groups throughout the study. Both pain and fatigue scores were very similar with no significant differences between groups at any time point. Higher pain intensity and greater fatigue scores correlated with lower 2MWT distances (Table 3) . Morphine consumption was also negatively correlated with 2MWT on Day 2. Those patients who walked less on Day 2 stayed in hospital longer. Analysis by univariate linear regression (Table 4) indicated that group (lidocaine or control), ASA, preoperative 2MWT, and difference between predicted and preoperative 2MWT were predictors of change in 2MWT ( preoperative2first postoperative day).
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Discussion
There are few published data about the course of recovery in the immediate period after surgery and the possible impact of interventions in modifying the outcome. We used the 2MWT to determine whether lidocaine infusion would influence in-hospital recovery of functional walking capacity. Although there was a significant decrease in the postoperative values of the 2MWT in both groups, the deterioration was significantly less in the lidocaine group during the first postoperative day. The average difference in distance covered was 26 m that can be considered to be clinically meaningful in a population at risk such as the early postoperative period. There was an overall negative correlation between the distance covered over 2 min and the pain intensity, fatigue score, and morphine consumption. Both groups recuperated by the third postoperative day, but were still well below preoperative levels.
The pattern of acute deterioration in functional walking capacity followed by recovery is what is expected from an index quantifying the impact of surgical stress. Several factors affect the ability to ambulate in the very early postoperative period, the commonest being severe blood loss, dizziness, and pain. None of our patients refused to walk, and except for one patient who bled during surgery, none of them were anaemic or felt dizzy during the walking test. The deterioration in 2MWT distance on the first postoperative day was greater than 50%, and overall negatively correlated with the intensity of pain, fatigue score, and morphine consumption. The decrease in 2MWT was greater on Day 1 in the control group; they required more morphine indicating a strong causative association between the walking distance covered (functional outcome) and pain (impairment as directly related to surgical stress). This would fit with the surgical outcome model previously proposed by our group, 8 whereby short-term changes like pain intensity might impact on short-term outcome (here functional mobility).
Baseline performance of the 2MWT was an independent predictor of deterioration, thus confirming other studies that demonstrated a relationship between preoperative health status and functional reserve, and the course of recovery. 7 12 13 It was rather surprising to observe a 60% decrease in 2MWT in both groups on the first postoperative day as these patients were clinically fit (most ASA I or II) and undergoing laparoscopic surgery. Several studies on the metabolic effects of laparoscopic surgery have shown a reduction in the inflammatory response to surgery, less pain, and shorter duration of hospital stay compared with laparotomy. 14 One would have therefore expected less deterioration in functional walking capacity and an earlier return to baseline in both groups. However, it is not known whether the observed decrease in 2MWT was because of the surgical stress itself or to the changes that are associated with the laparoscopy. On the third day after surgery, the distance covered increased significantly from Day 1 but remained significantly below baseline.
There is some difficulty in identifying suitable indicators to assess surgical recovery. Exercise tolerance is a good indicator of the impact of surgery, and the most accepted measure of exercise tolerance is the amount of oxygen consumed at maximal effort (VO 2 max). Unfortunately, specialized equipment is required for this measure and the test may be too demanding for a surgical patient. Very little published data exist on the use of walking tests to estimate in-hospital surgical recovery. Brooks and colleagues 15 measured the 2MWT in 122 patients undergoing cardiac surgery at baseline, immediately before discharge from hospital and 6 -8 weeks after discharge. The mean distance declined from baseline to hospital discharge by an average of 40%, and this returned to baseline at 6 -8 weeks follow-up. The authors found the test easy to administer, accepted by the patients, sensitive to the changes of cardiac surgery, and showed moderate correlation (0.44-0.48) with measures of physical functioning. More recently, the 6MWT, another measure of walking capacity, was reported to have constructive validity and sensitivity to changes as a measure of surgical recovery in a group of patients undergoing colon resection. 13 The 6MWT has been used to assess the effect of epidural analgesia 3 and 6 weeks after colorectal surgery, 12 and 4 weeks after laparoscopic nephrectomy. 16 Although the 2MWT, in contrast with the 6MWT and the 12MWT, is not reflective of exercise capacity or requirements of daily living, it can be used in hospital to assess walking ability or exercise capacity of the lower extremities. In view of the importance placed on the role of earlier mobilization in promoting fast-track surgery, the 2MWT could be a useful measure to document the progression of functional exercise capacity and possibly predict hospital discharge.
In the present study, lidocaine infusion had a significant impact on the 2MWT with patients in this group able to walk a longer distance over a short period of time. It is possible that lidocaine, with its anti-inflammatory action, 5 had an opioid-sparing effect as shown by a trend towards less PCA morphine consumption in the lidocaine group. 3 4 This study has some limitations. One disadvantage is that a 2MWT measures walking capacity at only one point and not throughout the day. In addition, walking represents only one type of physical activity. The 2MWT was collected only for the first 3 postoperative days and no relationship with self-reported outcome measures was studied. Nevertheless, this study is an attempt to address issues related to meaningful patient outcomes and how to accelerate the recovery process.
In summary, lidocaine infusion throughout surgery and for the first 24 postoperative hours attenuated the deterioration in postoperative 2MWT. Preoperative 2MWT performance and use of lidocaine were important predictors of change in functional walking capacity. Development and testing of measures of surgical recovery are needed in order to understand how to improve the recovery process. 
